Free Trial
NASDAQ:RGEN

Repligen Q2 2025 Earnings Report

Repligen logo
$121.74 -0.13 (-0.11%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$123.33 +1.59 (+1.31%)
As of 07/25/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen EPS Results

Actual EPS
N/A
Consensus EPS
$0.40
Beat/Miss
N/A
One Year Ago EPS
N/A

Repligen Revenue Results

Actual Revenue
N/A
Expected Revenue
$174.62 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Repligen Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, July 29, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Repligen Earnings Headlines

Leerink Partnrs Expects Increased Earnings for Repligen
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
What is Leerink Partnrs' Forecast for Repligen Q1 Earnings?
See More Repligen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Repligen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Repligen and other key companies, straight to your email.

About Repligen

Repligen (NASDAQ:RGEN) develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

View Repligen Profile

More Earnings Resources from MarketBeat